Sedative effect for diagnostic upper gastrointestinal endoscopy in children

The comparison assessment of sedative effect of intravenous ktamine and midazolam versus oral combination of midazolam and ketamin for dagnostic upper gastrointestinal endoscopy in children

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190529043750N2

Enrollment

100

Registered

2020-05-14

Start date

2020-01-20

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedation in endoscopy. During endoscopic examination

Interventions

Intervention 1: Intervention group 1: Oral Midazolam (Exir Company) 0.5 mg / kg with a maximum dose of 20 mg and intramuscular Ketamine (Tritau Company) with a dose of 0.5 mg / kg. Intervention 2: Int

Eligibility

Sex/Gender

All

Age

3 Years to 16 Years

Inclusion criteria

Inclusion criteria: Patients have not underlying problem Age 3 -16 years old

Exclusion criteria

Exclusion criteria: Respiratory diseases Heart diseases Kidney diseases Liver diseases Apparent neurological inability Hypersensitivity to benzodiazepines

Design outcomes

Primary

Measure	Time frame
Sedation. Timepoint: During and 1 hour after endoscopy. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Omrani-Rad

Babol University of Medical Sciences

Omraniradali@gmail.com+98113238301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026